Histamine H4 Receptor Pipeline Review, H2 2019
Summary
Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 The histamine H4 receptor is a member of the G proteincoupled receptor super family. H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histaminemediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function.
Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 3 respectively. Report covers products from therapy areas Dermatology, Immunology, Ear Nose Throat Disorders and Respiratory which include indications Atopic Dermatitis Atopic Eczema, Acute Sensorineural Hearing Loss, Allergies, Cystic Fibrosis, Hearing Disorders, Idiopathic Pulmonary Fibrosis and Plaque Psoriasis Psoriasis Vulgaris.
The latest report Histamine H4 Receptor Pipeline Review, H2 2019, outlays comprehensive information on the Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Scope
The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4
The report reviews Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 targeted therapeutics and enlists all their major and minor projects
The report assesses Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi013 or SP9144 or GPCR105 or HRH4 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope